Oral cavity squamous cell carcinoma

Summary

Oral cavity squamous cell carcinoma (MONDO:0004958) is a cancer (an umbrella term covering 7 Mondo subtypes) with 2 cohort genes (2 CIViC-evidence somatic drivers) and 188 clinical trials. Top therapeutic interventions include cisplatin, cetuximab, and indomethacin.

At a glance

• Classification: Cancer
• Prevalence: 1-9 / 100 000 (Europe) [Orphanet-validated]
• Umbrella term: 7 Mondo subtypes
• Cohort genes: 2
• Clinical trials: 188

Clinical features

Epidemiology

Prevalence records

1 prevalence record(s), Orphanet:

Type	Class	Value	Geography	Validation
Annual incidence	1-9 / 100 000	3.51	Europe	Validated

Identifiers

Disease identifiers

Field	Value
Canonical name	oral cavity squamous cell carcinoma
Mondo ID	MONDO:0004958
EFO	EFO:0000199
Orphanet	502363
DOID	DOID:0050866
NCIT	C4833
SNOMED CT	307502000
UMLS	C0585362
MedGen	108436
GARD	0017932
Anatomy (UBERON)	UBERON:0000165
Is cancer (heuristic)	yes

Also known as: mouth scc · mouth squamous cell carcinoma · OCSC · oral cavity scc · oral cavity squamous cell cancer · oral cavity squamous cell carcinoma · oral squamous cell carcinoma · scc of mouth · scc of oral cavity · scc of the mouth · scc of the oral cavity · squamous cell carcinoma of mouth · squamous cell carcinoma of oral cavity · squamous cell carcinoma of the mouth · squamous cell carcinoma of the oral cavity

Data availability: 391 cell lines.

Disease family

An umbrella term covering 7 Mondo subtypes.

Classification path: human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › head and neck carcinoma › head and neck squamous cell carcinoma › lip and oral cavity squamous cell carcinoma › oral cavity squamous cell carcinoma

Subtypes (7): tongue squamous cell carcinoma, maxillary sinus squamous cell carcinoma, squamous cell carcinoma of lip, squamous cell carcinoma of floor of mouth, squamous cell carcinoma of buccal mucosa, verrucous carcinoma of oral cavity, salivary gland squamous cell carcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 20 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Somatic driver evidence (intOGen + CIViC, cohort fanout)

Gene	intOGen role	Cancer types	CIViC
TP53	LoF	ACC,ALL,AML,ANGS,ANSC,BCC,BL,BLADDER,BLCA,BRCA,CCRCC,CEAD,CESC,CHOL,CHRCC,CLLSLL,COAD,COADREAD,CSCC,DLBCLNOS,EGC,ES,ESCA,ESCC,GB,GBC,GBM,GIST,HCC,HGGNOS,HNSC,LGGNOS,LIPO,LMS,LNM,LUAD,LUSC,MBL,MEL,MLYM,MT,NBL,NETNOS,NHL,NPC,NSCLC,OS,OVT,PAAD,PANCREAS,PAST,PCM,PLMESO,PRAD,PRCC,PROSTATE,RCC,READ,SACA,SARCNOS,SCLC,SIC,SKCM,SKIN,SOFT_TISSUE,STAD,STOMACH,THYM,UCEC,UCS,UTUC,VULVA,WDTC,WT	CIViC #45
GAS6			CIViC #2186

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
TP53	Orphanet:1333	Familial pancreatic carcinoma
TP53	Orphanet:145	Hereditary breast and/or ovarian cancer syndrome
TP53	Orphanet:1501	Adrenocortical carcinoma
TP53	Orphanet:210159	Adult hepatocellular carcinoma
TP53	Orphanet:251576	Gliosarcoma
TP53	Orphanet:251579	Giant cell glioblastoma
TP53	Orphanet:251899	Choroid plexus carcinoma
TP53	Orphanet:2807	Papilloma of choroid plexus
TP53	Orphanet:293199	Pleomorphic rhabdomyosarcoma
TP53	Orphanet:3318	Essential thrombocythemia
TP53	Orphanet:524	Li-Fraumeni syndrome
TP53	Orphanet:52688	Myelodysplastic syndrome
TP53	Orphanet:585909	B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)
TP53	Orphanet:667662	Breast implant-associated anaplastic large cell lymphoma
TP53	Orphanet:668	Osteosarcoma
TP53	Orphanet:67038	B-cell chronic lymphocytic leukemia
TP53	Orphanet:70573	Small cell lung cancer
TP53	Orphanet:96253	Cushing disease
TP53	Orphanet:99756	Alveolar rhabdomyosarcoma
TP53	Orphanet:99757	Embryonal rhabdomyosarcoma

Cohort genes → proteins

2 cohort genes, 2 distinct canonical proteins.

Evidence partition

Subset	Genes
civic_only	2

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
TP53	HGNC:11998	ENSG00000141510	P04637	Cellular tumor antigen p53	civic_evidence
GAS6	HGNC:4168	ENSG00000183087	Q14393	Growth arrest-specific protein 6	civic_evidence

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
TP53	Cellular tumor antigen p53	Multifunctional transcription factor that induces cell cycle arrest, DNA repair or apoptosis upon binding to its target DNA sequence.
GAS6	Growth arrest-specific protein 6	Ligand for tyrosine-protein kinase receptors AXL, TYRO3 and MER whose signaling is implicated in cell growth and survival, cell adhesion and cell migration.

Protein-family classification

Druggable: 0 · Difficult: 1 · Unknown: 1 · Druggable fraction: 0.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Transcription factor	1	4.1×	0.455
Other/Unknown	1	0.9×	0.805

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
TP53	Transcription factor	no		p53_tumour_suppressor, p53-like_TF_DNA-bd_sf, p53_tetrameristn
GAS6	Other/Unknown	no		EGF-type_Asp/Asn_hydroxyl_site, GLA_domain, EGF

Expression context

Cohort genes with no expression data: 0.

2 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	2
unknown	0

Top tissues across cohort

Tissue	Cohort genes
ganglionic eminence	1
tendon of biceps brachii	1
ventricular zone	1
ascending aorta	1
descending thoracic aorta	1
thoracic aorta	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
TP53	223	ubiquitous	marker	ventricular zone, ganglionic eminence, tendon of biceps brachii
GAS6	284	ubiquitous	marker	ascending aorta, thoracic aorta, descending thoracic aorta

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
TP53	22,736
GAS6	2,339

Structural data

PDB: 2 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
TP53	P04637	313
GAS6	Q14393	4

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 54. Enrichment computed across 2 evidence-associated genes (2 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 2 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Loss of function of TP53 in cancer due to loss of tetramerization ability	1	5710.0×	0.008	TP53
Regulation of TP53 Expression	1	2855.0×	0.008	TP53
Transcriptional activation of cell cycle inhibitor p21	1	1427.5×	0.008	TP53
Activation of NOXA and translocation to mitochondria	1	951.7×	0.008	TP53
RUNX3 regulates CDKN1A transcription	1	815.7×	0.008	TP53
Transport of gamma-carboxylated protein precursors from the endoplasmic reticulum to the Golgi apparatus	1	634.4×	0.008	GAS6
PI5P Regulates TP53 Acetylation	1	634.4×	0.008	TP53
Activation of PUMA and translocation to mitochondria	1	571.0×	0.008	TP53
Gamma-carboxylation of protein precursors	1	571.0×	0.008	GAS6
Removal of aminoterminal propeptides from gamma-carboxylated proteins	1	571.0×	0.008	GAS6
TP53 Regulates Transcription of Caspase Activators and Caspases	1	475.8×	0.008	TP53
TP53 Regulates Transcription of Death Receptors and Ligands	1	475.8×	0.008	TP53
Urea cycle	1	439.2×	0.008	TP53
Regulation of TP53 Activity through Association with Co-factors	1	407.9×	0.008	TP53
TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain	1	380.7×	0.008	TP53
Stabilization of p53	1	380.7×	0.008	TP53
TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest	1	356.9×	0.008	TP53
Formation of Senescence-Associated Heterochromatin Foci (SAHF)	1	335.9×	0.008	TP53
Zygotic genome activation (ZGA)	1	335.9×	0.008	TP53
Regulation of NF-kappa B signaling	1	317.2×	0.008	TP53
TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest	1	300.5×	0.008	TP53
SUMOylation of transcription factors	1	285.5×	0.008	TP53
TP53 Regulates Transcription of Genes Involved in Cytochrome C Release	1	271.9×	0.008	TP53
Regulation of TP53 Activity through Methylation	1	271.9×	0.008	TP53
TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain	1	259.6×	0.008	TP53
Regulation of TP53 Activity through Acetylation	1	228.4×	0.009	TP53
Pyroptosis	1	211.5×	0.009	TP53
Oncogene Induced Senescence	1	167.9×	0.011	TP53
Association of TriC/CCT with target proteins during biosynthesis	1	146.4×	0.012	TP53
Regulation of TP53 Degradation	1	146.4×	0.012	TP53

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 2 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
negative regulation of helicase activity	1	8426.0×	0.003	TP53
cellular response to actinomycin D	1	8426.0×	0.003	TP53
negative regulation of oligodendrocyte apoptotic process	1	8426.0×	0.003	GAS6
regulation of intrinsic apoptotic signaling pathway by p53 class mediator	1	8426.0×	0.003	TP53
negative regulation of G1 to G0 transition	1	8426.0×	0.003	TP53
negative regulation of renal albumin absorption	1	8426.0×	0.003	GAS6
cellular response to xenobiotic stimulus	2	240.7×	0.003	TP53, GAS6
positive regulation of mitochondrial membrane permeability	1	4213.0×	0.003	TP53
cellular response to vitamin K	1	4213.0×	0.003	GAS6
oligodendrocyte apoptotic process	1	4213.0×	0.003	TP53
negative regulation of glucose catabolic process to lactate via pyruvate	1	4213.0×	0.003	TP53
negative regulation of pentose-phosphate shunt	1	4213.0×	0.003	TP53
positive regulation of glomerular filtration	1	2808.7×	0.003	GAS6
fusion of virus membrane with host plasma membrane	1	2808.7×	0.003	GAS6
obsolete homolactic fermentation	1	2808.7×	0.003	TP53
signal transduction by p53 class mediator	1	2808.7×	0.003	TP53
negative regulation of miRNA processing	1	2808.7×	0.003	TP53
intrinsic apoptotic signaling pathway in response to hypoxia	1	2808.7×	0.003	TP53
regulation of fibroblast apoptotic process	1	2808.7×	0.003	TP53
T cell proliferation involved in immune response	1	2106.5×	0.004	TP53
positive regulation of programmed necrotic cell death	1	2106.5×	0.004	TP53
oxidative stress-induced premature senescence	1	2106.5×	0.004	TP53
B cell lineage commitment	1	1685.2×	0.004	TP53
T cell lineage commitment	1	1685.2×	0.004	TP53
mRNA transcription	1	1685.2×	0.004	TP53
positive regulation of RNA polymerase II transcription preinitiation complex assembly	1	1685.2×	0.004	TP53
positive regulation of thymocyte apoptotic process	1	1685.2×	0.004	TP53
cellular response to UV-C	1	1685.2×	0.004	TP53
hematopoietic stem cell migration to bone marrow	1	1685.2×	0.004	GAS6
negative regulation of interleukin-1 production	1	1404.3×	0.004	GAS6

Therapeutics

Drugs indicated for this disease

1 approved, 9 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Nivolumab	Approved (phase 4)
Albumin Human	Phase 3 (in late-stage trials)
Camrelizumab	Phase 3 (in late-stage trials)
Carboplatin	Phase 3 (in late-stage trials)
Cisplatin	Phase 3 (in late-stage trials)
Indomethacin	Phase 3 (in late-stage trials)
Melatonin	Phase 3 (in late-stage trials)
Paclitaxel	Phase 3 (in late-stage trials)
Tislelizumab	Phase 3 (in late-stage trials)
Zinc Ion	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Adebrelimab, Celecoxib, Durvalumab, Fluorouracil, Linrodostat, Metformin, Nimotuzumab, Omeprazole, Rivoceranib, Sargramostim, Sintilimab, Tegafur, Toripalimab, Trastuzumab, Tremelimumab, Uracil.

Drug target analysis

Approved (phase 4): 1 · Phase ≥3: 1 · Phased (≥1): 1 · Undrugged: 1

Druggability breadth: 2 of 2 evidence-associated genes (100%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

Symbol	Example approved molecule
TP53	NITROFURANTOIN

Top cohort targets by molecule count

Symbol	Molecules	Max phase
TP53	196	4
GAS6	0	0

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
NITROFURANTOIN	4	TP53
DIOSMIN	4	TP53
VERTEPORFIN	4	TP53
CANDESARTAN CILEXETIL	4	TP53
DIENESTROL	4	TP53
CLOTRIMAZOLE	4	TP53
COLCHICINE	4	TP53
NABUMETONE	4	TP53
SALMETEROL XINAFOATE	4	TP53
AMIODARONE HYDROCHLORIDE	4	TP53
FURAZOLIDONE	4	TP53
AMOXAPINE	4	TP53
RALOXIFENE HYDROCHLORIDE	4	TP53
NICARDIPINE HYDROCHLORIDE	4	TP53
SULCONAZOLE NITRATE	4	TP53
PYRITHIONE ZINC	4	TP53
LACTIC ACID	4	TP53
OXYMETHOLONE	4	TP53
CHLOROXINE	4	TP53
PROPIOLACTONE	4	TP53
CLOMIPRAMINE HYDROCHLORIDE	4	TP53
PHENYL AMINOSALICYLATE	4	TP53
THIORIDAZINE HYDROCHLORIDE	4	TP53
AMITRIPTYLINE HYDROCHLORIDE	4	TP53
ETHOPROPAZINE HYDROCHLORIDE	4	TP53
MECHLORETHAMINE HYDROCHLORIDE	4	TP53
ECONAZOLE NITRATE	4	TP53
TRIFLUPROMAZINE HYDROCHLORIDE	4	TP53
PROCHLORPERAZINE EDISYLATE	4	TP53
DEQUALINIUM CHLORIDE	4	TP53

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 0.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
TP53	869	Binding:775, ADMET:83, Functional:10, Toxicity:1
GAS6	1	Binding:1

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

Symbol	ChEMBL assays
TP53	869

Pharmacogenomics

Cohort genes with a PharmGKB record: 2; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Drug repurposing candidates

30 approved/phased drugs hit cohort targets but don’t yet appear in disease-level clinical trials. Target-inhibition rationale is strongest for cancer driver genes; a bioactivity hit is a screening signal, not a treatment claim.

Compound	Max phase	Cohort target (bioactivity)
NITROFURANTOIN	4	TP53
DIOSMIN	4	TP53
VERTEPORFIN	4	TP53
CANDESARTAN CILEXETIL	4	TP53
DIENESTROL	4	TP53
CLOTRIMAZOLE	4	TP53
COLCHICINE	4	TP53
NABUMETONE	4	TP53
SALMETEROL XINAFOATE	4	TP53
AMIODARONE HYDROCHLORIDE	4	TP53
FURAZOLIDONE	4	TP53
AMOXAPINE	4	TP53
RALOXIFENE HYDROCHLORIDE	4	TP53
NICARDIPINE HYDROCHLORIDE	4	TP53
SULCONAZOLE NITRATE	4	TP53
PYRITHIONE ZINC	4	TP53
LACTIC ACID	4	TP53
OXYMETHOLONE	4	TP53
CHLOROXINE	4	TP53
PROPIOLACTONE	4	TP53
CLOMIPRAMINE HYDROCHLORIDE	4	TP53
PHENYL AMINOSALICYLATE	4	TP53
THIORIDAZINE HYDROCHLORIDE	4	TP53
AMITRIPTYLINE HYDROCHLORIDE	4	TP53
ETHOPROPAZINE HYDROCHLORIDE	4	TP53
MECHLORETHAMINE HYDROCHLORIDE	4	TP53
ECONAZOLE NITRATE	4	TP53
TRIFLUPROMAZINE HYDROCHLORIDE	4	TP53
PROCHLORPERAZINE EDISYLATE	4	TP53
DEQUALINIUM CHLORIDE	4	TP53

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	1	TP53
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	0
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	1	GAS6

Undrugged target profiles

1 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
GAS6	1	—

Clinical trials & evidence

Clinical trials

Clinical trials: 188.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	76
PHASE2	55
PHASE1	20
PHASE1/PHASE2	11
PHASE3	9
EARLY_PHASE1	9
PHASE2/PHASE3	8

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04333537	PHASE2/PHASE3	RECRUITING	Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
NCT05125055	PHASE2/PHASE3	RECRUITING	Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC
NCT05721755	PHASE3	ACTIVE_NOT_RECRUITING	Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck
NCT05798793	PHASE3	RECRUITING	Neoadjuvant Anti-PD-1 Immunotherapy With Chemotherapy in Resectable Locally Advanced Oral Squamous Cell Carcinoma
NCT05893888	PHASE2/PHASE3	RECRUITING	A Study Evaluating the Safety and Efficacy of PRV111, PRV211, and PRV131 in Subjects With Oral and Lung Cancers
NCT06030440	PHASE2/PHASE3	RECRUITING	De-Intensification of Postoperative Radiotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck
NCT06258811	PHASE3	RECRUITING	Neoadjuvant Immunochemotherapy for LAOSCC
NCT06589804	PHASE3	RECRUITING	Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
NCT07371611	PHASE3	RECRUITING	Sintilimab Plus Chemotherapy as Neoadjuvant and Adjuvant Treatment for Locally Advanced Oral Squamous Cell Carcinoma
NCT00050388	PHASE3	COMPLETED	Phase II Trial of Allovectin-7® for Head and Neck Cancer
NCT01265849	PHASE3	COMPLETED	Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity
NCT01542931	PHASE2/PHASE3	COMPLETED	TPF Induction Chemotherapy for Locally Advanced and Resectable Oral Squamous Cell Carcinoma
NCT02236936	PHASE3	TERMINATED	Parenteral Nutrition for Patients Treated for Locally Advanced Inoperable Tumors of the Head and Neck
NCT02923258	PHASE2/PHASE3	COMPLETED	Postoperative CCRT With Docetaxel vs Cisplatin in High Risk Oral Cavity Cancer
NCT03258554	PHASE2/PHASE3	COMPLETED	Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin
NCT04137627	PHASE3	COMPLETED	Melatonin Effect in Combination With Neoadjuvant Chemotherapy to Clinical Response in Locally Advanced Oral Squamous Cell Carcinoma
NCT06016400	PHASE2/PHASE3	UNKNOWN	Using Vitamin D to Reduce Oral Mucosal Inflammation in Chemotherapy Patients With Oral Squamous Cell Carcinoma
NCT00494182	PHASE2	ACTIVE_NOT_RECRUITING	Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell Cancer
NCT03085147	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	A Dye for the Detection of Cancer of the Tongue and Mouth
NCT03468218	PHASE2	ACTIVE_NOT_RECRUITING	Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer
NCT03784066	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Durvalumab With or Without Tremelimumab in Resectable Locally Advanced Squamous Cell Carcinoma of the Oral Cavity
NCT03854032	PHASE2	ACTIVE_NOT_RECRUITING	Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and Neck
NCT04191460	PHASE2	RECRUITING	Fluorescence-guided Surgery Using cRGD-ZW800-1 in Oral Cancer
NCT04671667	PHASE2	RECRUITING	Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
NCT04718415	PHASE2	ACTIVE_NOT_RECRUITING	Neoadjuvant Sintilimab in Combination With Carboplatin and Nab-paclitaxel in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma
NCT04858269	PHASE2	ACTIVE_NOT_RECRUITING	First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients
NCT04862650	PHASE2	ACTIVE_NOT_RECRUITING	Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
NCT05069857	PHASE2	RECRUITING	Neoadjuvant Personalized Anti-PD-1 and Anti-VEGFR Therapy in OSCC Patients
NCT05098119	PHASE2	RECRUITING	Neoadjuvant Sintilimab Combined With Reduction of Cycles of Chemotherapy in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma (OOC-002)
NCT05136196	PHASE2	RECRUITING	BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
NCT05144698	PHASE1/PHASE2	RECRUITING	RAPA-201 Therapy of Solid Tumors
NCT05172258	PHASE2	ACTIVE_NOT_RECRUITING	Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck
NCT05312710	PHASE2	ACTIVE_NOT_RECRUITING	Safety and Efficacy of APG-157 in Head and Neck Cancer
NCT05681039	PHASE2	RECRUITING	Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).
NCT05862168	PHASE2	RECRUITING	Neoadjuvant Treatment of Tislelizumab Combined Chemotherapy for Locally Advanced Oral Squamous Cell Carcinoma ：A Single-arm, Prospective, Phase II Trial
NCT06009861	PHASE2	ACTIVE_NOT_RECRUITING	Neoadjuvant Tislelizumab Plus Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer (NeoSPOT)
NCT06097468	PHASE1/PHASE2	RECRUITING	Nisin in Oral Cavity Squamous Cell Carcinoma (OCSCC)
NCT06532279	PHASE2	RECRUITING	Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
NCT06627270	PHASE2	RECRUITING	Antibiotic Treatment Effects on Intratumoral Bacteria Modulation in Surgical Patients With Oral Cancer
NCT06636734	PHASE2	RECRUITING	Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CISPLATIN	4	23
CETUXIMAB	4	3
INDOMETHACIN	4	2
ALBUMIN HUMAN	4	1
ALFACALCIDOL	4	1
CABOZANTINIB	4	1
DURVALUMAB	4	1
FLUDEOXYGLUCOSE F 18	4	1
OLAPARIB	4	1
SODIUM THIOSULFATE	4	1
TEGAFUR	4	1
TISLELIZUMAB	4	1
VORINOSTAT	4	1
MONALIZUMAB	3	1
NIMOTUZUMAB	3	1
ZINC ION	3	1
IRX-2	2	2
BIROPEPIMUT-S	2	1
ETIMUPEPIMUT	2	1
HILTONOL	2	1
HPPH	2	1
IMSAPEPIMUT	2	1
CHEMBL1201279	0	1
CHEMBL3883608	0	1
CHEMBL4215501	0	1
CHEMBL4849721	0	1
CHEMBL3753202	0	1
EXELIXIS	0	1